Department of Oncology, General Hospital, Jinan Command of the People's Liberation Army, Jinan, China.
PLoS One. 2012;7(12):e52704. doi: 10.1371/journal.pone.0052704. Epub 2012 Dec 20.
Lymphatic vessel invasion (LVI) exerts an important process in the progression and local spread of cancer cells. However, LVI as a prognostic factor for survival in non-small cell lung cancer (NSCLC) remains controversial.
METHODOLOGY/PRINCIPAL FINDINGS: A meta-analysis of published studies from PubMed and EMBASE electronic databases was performed to quantity the effects of LVI on both relapse-free survival and overall survival for patients with NSCLC. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to assess the strength of these effects. This meta-analysis included 18,442 NSCLC patients from 53 eligible studies. LVI appeared in 32.1% (median; range, 2.8% to 70.9%) of tumor samples. In all, patients with LVI were 2.48 times more likely to relapse by univariate analysis (95% CI: 1.92-3.22) and 1.73 times by multivariate analysis (95% CI: 1.24-2.41) compared with those without LVI. For the analyses of LVI and overall survival, the pooled HR estimate was 1.97 (95% CI: 1.75-2.21) by univariate analysis and 1.59 (95% CI: 1.41-1.79) by multivariate analysis. Multivariate analysis showed a risk was 91% higher for recurrence (HR =1.91, 95% CI: 1.14-2.91) and 70% higher for mortality (HR=1.70, 95% CI: 1.38-2.10) in LVI-positive I stage patients compared with LVI-negative I stage patients. Subgroup analyses showed similar significant adjusted risks for recurrence and death in adenocarcinomas, and a significant adjusted risk for death in studies that utilized elastic staining with or without immunohistochemistry in defining LVI.
CONCLUSIONS/SIGNIFICANCE: The present study indicates that LVI appears to be an independent poor prognosticator in surgically managed NSCLC. NSCLC patients with LVI would require a more aggressive treatment strategy after surgery. However, large, well-designed prospective studies with clinically relevant modeling and standard methodology to assess LVI are required to address some of these important issues.
淋巴管浸润(LVI)在癌细胞的进展和局部扩散中发挥着重要作用。然而,LVI 作为非小细胞肺癌(NSCLC)患者生存的预后因素仍存在争议。
方法/主要发现:对 PubMed 和 EMBASE 电子数据库中已发表研究的荟萃分析,以量化 LVI 对 NSCLC 患者无复发生存和总生存的影响。使用风险比(HR)和 95%置信区间(95%CI)来评估这些影响的强度。该荟萃分析纳入了 53 项合格研究中的 18442 例 NSCLC 患者。LVI 出现在 32.1%(中位数;范围 2.8%至 70.9%)的肿瘤样本中。在所有患者中,LVI 阳性患者较 LVI 阴性患者更易发生复发,单因素分析(95%CI:1.92-3.22)为 2.48 倍,多因素分析(95%CI:1.24-2.41)为 1.73 倍。对于 LVI 和总生存的分析,单因素分析的合并 HR 估计值为 1.97(95%CI:1.75-2.21),多因素分析为 1.59(95%CI:1.41-1.79)。多因素分析显示,与 LVI 阴性 I 期患者相比,LVI 阳性 I 期患者的复发风险增加 91%(HR=1.91,95%CI:1.14-2.91),死亡风险增加 70%(HR=1.70,95%CI:1.38-2.10)。亚组分析显示,在腺癌中,复发和死亡的调整后风险具有相似的显著意义,在使用弹性染色和/或免疫组织化学定义 LVI 的研究中,死亡的调整后风险具有显著意义。
结论/意义:本研究表明,LVI 似乎是手术治疗 NSCLC 的独立不良预后因素。LVI 阳性的 NSCLC 患者术后需要更积极的治疗策略。然而,需要进行大样本、精心设计的前瞻性研究,采用具有临床相关性的建模和标准方法来评估 LVI,以解决其中的一些重要问题。